Iperten (Manidipine Dihydrochloride)

Manidipine blocks L‑type calcium channels in vascular smooth muscle, preventing calcium entry that causes muscle contraction. This results in vasodilation of peripheral arteries, decreasing systemic vascular resistance and ultimately lowering arterial blood pressure.

The prescribed dose of Iperten is determined by the treating physician based on the patient’s clinical condition, blood pressure response, and tolerability. Dosing regimens are individualized, and patients should follow the prescriber’s specific instructions.

Safety of manidipine during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and such decisions must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Iperten product page at gnhindia.com, providing the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details and necessary import documentation.

Compared with other calcium‑channel blockers, manidipine offers a long‑acting antihypertensive effect with a favorable tolerability profile and may cause less reflex tachycardia than some dihydropyridines. Choice of therapy should be individualized based on patient characteristics and clinical response.

Iperten tablets should be stored at room temperature, below 25 °C, in the original blister pack, protected from moisture and light. Proper storage helps maintain the drug’s stability throughout its shelf life.

Iperten is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water.

The most serious adverse events linked to Iperten include severe hypotension, hepatic dysfunction, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, jaundice, or swelling of the face and throat.

Iperten is contraindicated in individuals with known hypersensitivity to manidipine or other calcium‑channel blockers, and in patients with severe aortic stenosis. Caution is advised for those with significant liver impairment or unstable cardiac conditions.